Please login to the form below

Not currently logged in
Email:
Password:

fedratinib

This page shows the latest fedratinib news and features for those working in and with pharma, biotech and healthcare.

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

It also comes on the heels of  another significant approval of Celgene’s JAK inhibitor Inrebic (fedratinib), which scored an FDA nod in August.

Latest news

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis

  • Deal Watch January 2018

    The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company -  remaining 90%. 9

  • Pharma deals during November 2013 Pharma deals during November 2013

    While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...